Journal article
Loss of STARD 10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status
Niamh C Murphy, Andrew V Biankin, Ewan KA Millar, Catriona M McNeil, Sandra A O'Toole, Davendra Segara, Paul Crea, Monilola A Olayioye, C Soon Lee, Stephen B Fox, Adrienne L Morey, Michael Christie, Elizabeth A Musgrove, Roger J Daly, Geoffrey J Lindeman, Susan M Henshall, Jane E Visvader, Robert L Sutherland
INTERNATIONAL JOURNAL OF CANCER | WILEY | Published : 2010
DOI: 10.1002/ijc.24826
Abstract
The phospholipid transfer protein STARD10 cooperates with c-erbB signaling and is overexpressed in Neu/ErbB2 breast cancers. We investigated if STARD10 expression provides additional prognostic information to HER2/neu status in primary breast cancer. A published gene expression dataset was used to determine relationships between STARD10 and HER2 mRNA levels and patient outcome. The central findings were independently validated by immunohistochemistry in a retrospective cohort of 222 patients with breast cancer with a median follow-up of 64 months. Kaplan-Meier and Cox proportional hazards analyses were used for univariate and multivariate analyses. Patients with low STARD10 or high HER2 tumo..
View full abstractGrants
Funding Acknowledgements
National Health and Medical Research Council of Australia, Victorian Breast Cancer Research Consortium Inc. (Australia), the Cancer Institute of NSW, the Petre Foundation, the RT Hall Trust